iShares Global Healthcare

New report shows Eli Lilly and Novo Nordisk dominate GLP-1 drug citations in AI tools

Lilly China Launches "Tuo Hu Chang An" Patient Assistance Program to Support IBD Patients

UCB's Bimzelx Beats AbbVie's Skyrizi in Head-to-Head Psoriatic Arthritis Study with Superior Joint Outcomes

Johnson & Johnson Expected to Grow Sales 7% in 2026, Seen as Strong Investment Due to Stable Model and Dividend History

Zacks Raises UnitedHealth's Q1 2027 EPS Estimate to $6.87

Eli Lilly & UNICEF Launch US$50m Partnership Program for Childhood Chronic Diseases

WHO confirms Merck's Ervebo vaccine as candidate for Ebola prevention

Multiple Institutional Investors Disclose Increased Stakes in UnitedHealth Group on May 19, 2026

Lilly Asia Ventures Participates in Accro Bioscience's $50 Million Series C Financing

Institutional Investor Larson Financial Group LLC Reduces Stake in Eli Lilly

Investment firm Gambit Capital Management makes a new $26.54 million investment in Eli Lilly

Wells Fargo Raises UnitedHealth Group's Price Target to $397

Japan Approves Eli Lilly's Zepbound for Obstructive Sleep Apnea

Eli Lilly Scales Up AI-Driven Drug R&D and Production with Dell Solutions

Merck Plans to Issue $6 Billion in Bonds to Fund Terns Pharmaceutical Acquisition

Judge grants Luigi Mangione's request to suppress evidence in UnitedHealth CEO murder case

UnitedHealth Group will hold its Annual General Meeting on June 2, 2026

Harbour BioMed releases positive preclinical obesity data on its potential rival drug, LET003

Merck Announces Experimental Endometrial Cancer Drug Meets Primary Endpoint in Late-Stage Trial

Novo Nordisk plans to launch Wegovy oral weight-loss drug outside the US, intensifying competition with Eli Lilly

NextNRG

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

InMed Pharmaceuticals

Amesite

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

Meiwu Tech

CN Energy

MetaVia

Generation Income Properties

Co-Diagnostics

Pinned News

置顶新闻

Zacks Research Issues Optimistic Estimate for UNH Earnings

UNHG

Zacks Research has raised its Q1 2027 earnings estimate for UnitedHealth Group (NYSE:UNH) to $6.87 per share, up from $6.77. The consensus estimate for the full-year earnings is $18.29 per share. Various analysts have given mixed ratings, with an average rating of 'Moderate Buy' and a price target of $381.83. UNH shares opened at $390.44, with a market cap of $354.57 billion.

Market Beat

Unitedhealth

Health Care Select Sector SPDR

SPDR S&P Health

Leverage Shares 2X Long UNH Daily ETF

iShares US Healthcare Providers

VG Health

Berkshire Hathaway

Berkshire Hathaway B

HSBC

HSBC HOLDINGS

HSBC Holdings Plc

Jefferies Financial

Barclays

Piper Sandler Cos

UBS Group AG

HSBC 5xShortSG241213

Investors seeking reliable dividend stocks may consider ExxonMobil, Johnson & Johnson, and Coca-Cola. ExxonMobil has raised its dividend for 43 years, with a forward yield of 2.6% and expected EPS growth of 19% CAGR from 2025 to 2028. Johnson & Johnson, with a 64-year dividend history and a 2.3% yield, focuses on pharmaceuticals and medical devices, expecting 8% EPS growth. Coca-Cola, also with a 64-year dividend record and a 2.6% yield, adapts to market changes and anticipates 6% EPS growth, maintaining high margins.

- The article discusses the risks and strategies for investing in the stock market, emphasizing long-term holding for better returns.  
- It highlights three blue chip stocks: ExxonMobil, Johnson & Johnson, and Coca-Cola, known for their stability and consistent dividend payments.  
- Each company's growth potential and current valuation suggest they remain solid investment choices amid market volatility.

Motley Fool

Exxon Mobil

Johnson & Johnson

Coca Cola

ProShares Ultra Consumer Staples

SPDR FD Consumer Staples

S&P 500

VG S&P 500

These 3 Dividend Stocks Are as Close to a Sure Thing as Investing Gets

UCBJY

LABU

UCB announced positive results from the phase 3 BE BOLD trial, showing bimekizumab outperformed risankizumab in treating active psoriatic arthritis. At week 16, 49.1% of bimekizumab patients achieved ACR50 compared to 38.4% for risankizumab. Early improvements were noted as early as week 4. No new safety concerns were reported, although mild to moderate candida infections were more common with bimekizumab.

PharmaTimes

UCB S.A.

United Community Banks

Direxion S&P Biotech Bull 3X

VanEck Biotech ETF

Invesco Nasdaq Biotechnology ETF

ALPS Medical Breakthrough

SPDR S&P Biotech

iShares Biotechnology ETF

Ark Genomic Revolution ETF

iShares US Pharma

First Trust NYSE Arca Biotech Index Fd

Invesco Biotechnology & Genome ETF

Proshares Ultra Nasdaq Biotech

UCB reports positive outcomes for bimekizumab in psoriatic arthritis

PILL

The Supreme Court declined to hear appeals from six drugmakers against Medicare's drug price negotiations. This decision is projected to save patients $1.5 billion and Medicare $6 billion in the first year. Ongoing legal challenges in lower courts may lead to future Supreme Court reviews.

Bristol Myers Squibb

Direxion Pharma & Medical Bull 3X

Supreme Court rejects drugmakers’ bid to halt Medicare price talks

BAYN

BAYRY

Bayer AG announced that the U.S. FDA has granted Priority Review for Asundexian, an oral Factor Xla inhibitor aimed at preventing secondary strokes. This follows positive results from the Phase 3 OCEANIC-STROKE trial. The Priority Review designation highlights the urgency for new secondary stroke prevention methods. Stroke is a leading cause of death in the U.S., with 795,000 cases annually. Bayer's stock closed at $11.02, up 1.10%.

nasdaq

Bayer AG

Bayer

Nasdaq

Bayer Aktiengesellschaft

Bayer Granted Priority Review For Asundexian In Secondary Stroke Prevention

ELIL

LLYX

Donald Trump disclosed stock purchases of up to $680,000 in Eli Lilly as Medicare initiatives advanced GLP-1 drug coverage. The investments coincided with policies benefiting the drugmaker's obesity treatments. Trump's purchases also included shares in West Pharmaceutical Services, valued between $250,000 and $500,000. A spokesperson stated that his investments are managed independently by third-party institutions. Eli Lilly shares rose 2.73% to $1015.09, gaining 9.4% over the past month.

benzinga_article

Eli Lilly

West Pharmaceutical

Direxion Daily LLY Bull 2X Shares

Defiance Daily Target 2X Long LLY ETF

Thomson Reuters

Trump's Stock Picks Perfectly Timed With New Medicare Rules: Report

GILD

ProShare Advisors LLC increased its stake in Gilead Sciences, Inc. by 39.1% in Q4, acquiring 623,752 shares, bringing its total to 2,217,290 shares valued at $272.15 million. Other institutional investors also adjusted their holdings. Gilead's stock opened at $129.67, with a market cap of $160.99 billion. The company reported $2.03 EPS, exceeding estimates, and announced a quarterly dividend of $0.82 per share.

Gilead Sciences

Gilead Sciences, Inc.

ProShare Advisors LLC Buys 623,752 Shares of Gilead Sciences, Inc. $GILD

NTHI

NeOnc Technologies Holdings, Inc. reported progress in its glioma programs, completing a Phase 1 study of NEO212 and enrolling in a Phase 2a trial of NEO100. The company improved its financial position with a $10 million PIPE financing and reduced its quarterly net loss to $8.8 million. Analysts rate NTHI stock as a Buy with a $20.00 target, though concerns about financial performance persist. NeOnc focuses on CNS cancers, developing drugs under FDA Fast-Track status.

Tip Ranks

Neonc Tech

NeOnc Advances Glioma Programs and Strengthens Financial Position

Johnson & Johnson (NYSE: JNJ) is highlighted as a strong investment choice due to its robust business model, AAA credit rating, and a history of 64 consecutive dividend increases. Despite facing legal challenges and potential government price negotiations, the company is expected to grow sales by 7% year-over-year by 2026. Its diversified portfolio and essential products position it well to navigate economic downturns, making it a reliable option for investors seeking stability.

SPDR S&P Health Equip

iShares US Medical Devices

NVIDIA

Intel

S&P Global

NVIDIA Corporation

Meet the Dividend King With a Higher Credit Rating Than the U.S. Government

NBIX

SLNO

Neurocrine Biosciences, Inc. presented new findings on INGREZZA's impact on mild tardive dyskinesia at the APA 2026 meeting, showing significant improvements in patient functional status. The company also completed its acquisition of Soleno Therapeutics for $2.9 billion, enhancing its rare disease portfolio. INGREZZA is FDA-approved for treating tardive dyskinesia and chorea associated with Huntington's disease. Neurocrine's stock closed at $157.21, down 0.76%, but rose 0.50% in after-hours trading.

Neurocrine Biosciences

Soleno Therapeutics

Goldman Sachs

GS Hldg R

Neurocrine Unveils New INGREZZA Findings In Mild Tardive Dyskinesia At APA 2026; Closes Soleno Deal

JPMorgan Chase & Co. has lowered its price target for HCA Healthcare from $535.00 to $490.00, maintaining a 'neutral' rating. The stock currently has a consensus rating of 'Moderate Buy' with an average target price of $515.77. HCA's stock traded down to $405.77, with a market cap of $90.02 billion. Analysts forecast an EPS of 30.07 for the current fiscal year.

HCA Healthcare

JPMorgan Chase

KeyCorp

JPMORGAN CHASE & CO. 4.20% DEP SHS REPSTG 1/400TH PFD SER MM

JPMORGAN CHASE & CO. 6%NON CUM DEP SHS REP 1/400TH PFD SER EE

JPMORGAN CHASE & CO. DEP REP 1/400TH (5.75% NON CUM PFD DD)

JPMORGAN CHASE & CO. 4.625% DEP SH RE 1/400TH INT NO CU PF LL

JPMorgan Chase & Co.

JPMORGAN CHASE & CO. 4.55% DEP SHS REPSTG 1/400TH PFD SER JJ

JPMORGAN CHASE & CO. 4.75 DEP SHS REP 1/400 NCUM PFD SR GG

KEYCORP DEP SHS REP 1/40TH NON CUM PER PFD SER G

KEYCORP DEP SHS REPSTG 1/40TH INT PERP NON CUM H

KEYCORP DEP SHS REP 1/40TH PERP PFD SER F USD25

KEYCORP DEP SHS REP 1/40TH NON CUM PFD SER E

HCA Healthcare (NYSE:HCA) Price Target Cut to $490.00 by Analysts at JPMorgan Chase & Co.

iShares Global Healthcare(IXJ.US)